 |
| Global Cancer Biopsy Market Growth |
The global Cancer Biopsy Market is estimated to be valued at US$ 25.61 Bn in 2023 and is expected to
exhibit a CAGR of 14.% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Cancer biopsy is a medical procedure that involves extracting samples of
suspicious tissues for examination and testing under a microscope. It helps in
the diagnosis of cancer by identifying cancerous (malignant) or precancerous
(non-malignant) cells. The market has witnessed significant growth due to the
growing prevalence of cancer and rising awareness about early detection of
cancer.
Market key trends:
One of the key trends in the cancer biopsy market is the introduction of liquid
biopsy. Liquid biopsy is a non-invasive blood-based test that analyzes
circulating tumor cells, circulating tumor DNA, and exosomes to detect cancer
at early stages. It provides key insights like tumor mutations without the need
for surgery. This new technology enables personalized treatment options and
monitors treatment effectiveness over time. It is gaining popularity as it is
less invasive and easy to conduct for cancers that are difficult to biopsy such
as lung cancer and ovarian cancer.
Segment Analysis
The global cancer biopsy market is segmented based on technique, application,
end user, and region. Based on technique, the market is segmented into needle
biopsy, surgical biopsy, and curettage biopsy. The needle biopsy segment
accounted for the largest market share in 2022, owing to its minimally invasive
nature, improved targeting capabilities, and wider adoption. The surgical
biopsy segment is expected to witness high growth during the forecast period
due to increasing preference for surgical methods for lung, breast, and
prostate cancer diagnosis.
Key Takeaways
The Global
Cancer Biopsy Market Growth is expected to witness high growth,
exhibiting a CAGR of 14% over the
forecast period, due to increasing incidences of cancer and growing preference
for minimally invasive biopsy procedures.
By region, North America dominated the global market in 2022 and is expected to
maintain its dominance during the forecast period owing to the growing demand
for advanced cancer diagnostic techniques, availability of funding for cancer
research, and rising cancer incidence in the US and Canada. Asia Pacific is
anticipated to exhibit the fastest growth during the forecast period due to
improving healthcare infrastructure, increasing healthcare expenditures, rising
awareness about cancer diagnosis, and expansion of private hospitals &
diagnostic centers in countries such as India and China.
Key players operating in the cancer biopsy market include QIAGEN, Illumina,
Inc., Angle PLC, Myriad Genetics, COUNSYL, Inc., Hologic, Inc., Biocept, Inc.,
Thermo Fisher Scientific, Inc., Danaher, F. Hoffmann-La Roche Ltd., Epigenomics
AG, BD (Becton, Dickinson and Company), and Helio Health (Laboratory for
Advanced Medicine), among others. Major players are focusing on new product
launches, expansions, mergers & acquisitions, and collaborations to gain a
competitive edge in the market. For instance, in November 2021, QIAGEN launched
a liquid biopsy diagnostic assay QuantiFERON-TB Gold Plus for tuberculosis
testing in blood samples to expand its footprints in the cancer biopsy market.
Get
More Insights On This Topic: https://www.pressreleasebulletin.com/cancer-biopsy-market-demand/